TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02155582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: 0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: 0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.
Study: NCT01016483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study: NCT03497117

Intervention type: DRUG
Group type: OTHER
Intervention: MRI with PFP
Description: * Description: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.
Study: NCT01016483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT00038194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT03964012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NmCV-5
Description: Polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysaccharide antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to C reactive material (CRM) protein. The diluent is Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra
Description: Menactra is available as ready to use solution containing polysaccharide antigens A,C,Y\&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine
Study: NCT02192710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electronic tab
Description: classic use of an electronic tab with age specific games

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam oral intake
Study: NCT04632329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Treatment via the Mercury Multi-Pressure Dial
Description: Negative Pressure Treatment via the Mercury Multi-Pressure Dial
Study: NCT01128972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride
Description: Test fluoride toothpaste and test fluoride mouth rinse
Study: NCT02554188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza (flu) vaccine
Description: Seasonal influenza (flu) vaccine~* Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old~* Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: A 5-day low calorie fasting-mimicking diet
Study: NCT03080974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation
Description: Non-thermal ablation of tumor
Study: NCT01128972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride
Description: Test fluoride toothpaste and test fluoride mouth rinse
Study: NCT02186132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine 0.6 mg
Description: Atropine 0.6 mg intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine 1.2 mg
Description: Atropine 1.2 mg intravenous
Study: NCT03676985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKAB001 5mg/kg
Description: 5mg/kg/times bi-week IV administration of ZKAB001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKAB001 10mg/kg
Description: 10mg/kg/times bi-week IV administration of ZKAB001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKAB001 15mg/kg
Description: 15mg/kg/times bi-week IV administration of ZKAB001
Study: NCT01163032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20 mg tasimelteon capsules, PO daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, PO daily for 6 months
Study: NCT04159961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ211
Description: Inject the Drug into submental fat and abdominal fat via subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ211
Description: Inject the Drug into submental fat and abdominal fat via subcutaneous
Study: NCT02192086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: goal directed fluid therapy
Description: The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg \* wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values).
Study: NCT01128972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride
Description: Test fluoride toothpaste and test fluoride mouth rinse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monoflurophosphate
Description: United Kingdom marketed fluoride toothpaste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Sterile water rinse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile water
Description: Sterile water rinse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile water
Description: Sterile water rinse
Study: NCT03760380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sole 1 - Neutral
Description: Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability. This is defined as the location which creates the smallest amount of instability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sole 1 - Offset
Description: Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sole 1 - Offset
Description: Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sole 2 - Neutral
Description: Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability.This is defined as the location which creates the smallest amount of instability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sole 2 - Offset
Description: Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sole 2 - Offset
Description: Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
Study: NCT04159961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ211
Description: Inject the Drug into submental fat and abdominal fat via subcutaneous
Study: NCT01786746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy. 12 sessions.
Study: NCT03884348

Intervention type: DRUG
Intervention: proton pump inhibitor, amoxicillin, clarithromycin
Description: non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin

Intervention type: DRUG
Intervention: proton pump inhibitor, amoxicillin, metronidazole
Description: clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole
Study: NCT03677960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical ABI-1968 cream
Description: Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical ABI-1968 cream
Description: Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical ABI-1968 cream
Description: Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29
Study: NCT00736190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300-mg tablet (marketed formulation) taken orally once daily
Study: NCT03504020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG Belt Research System
Description: The ECG Belt Research System is used to identify the best vector and programming parameters.
Study: NCT03065751

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmaexchange
Description: TPE against fresh frozen plasma
Study: NCT03704103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iSage
Description: The provider will choose a treatment algorithm within the iSage app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The patient is instructed to perform daily fasting glucose measurements and follow the app's recommendations for insulin adjustment.
Study: NCT01485068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Danubio paclitaxel-eluting balloon
Description: Inflation of the Danubio Paclitaxel Eluting Balloon in in-stent restenosis lesions.
Study: NCT04200833

Intervention type: DRUG
Intervention: Golimumab
Description: subcutaneous injection
Study: NCT02342873

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NS-guided interscalene block
Description: Patients received a standard single injection interscalene block using the modified lateral approach of Borgeat. The interscalene brachial plexus was identified using an insulated needle connected to a nerve stimulator. An insulated needle attached to a nerve stimulator was used to identify the brachial plexus. Placement of the needle was considered adequate if the deltoid, triceps, pectoralis, or biceps muscle motor response was still present at 0.2 - 0.5mA. Ropivacine 0.75% 20ml was used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided interscalene block
Description: Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.75% ropivacaine is injected
Study: NCT02777307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemopatch Sealing Hemostat
Description: Place of Hemopatch Sealing Hemostat after laparoscopic cholecistectomy
Study: NCT01690780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral morphine
Description: oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
Study: NCT04071613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Route: IV bolus injection Frequency: once only, within 4.5 hours of stroke onset

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous tissue plasminogen activator (tPA)
Description: Route: Intravenous (IV) infusion (10% as bolus and the remainder over 60 minutes) Frequency: once only, within 4.5 hours of stroke onset
Study: NCT04306601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Focused Ultrasound
Description: Low-intensity focused ultrasound brain stimulation using focused ultrasound system (NS-US100; NEUROSONA Co. Ltd., Seoul, Korea)
Study: NCT03911206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Description: IMT exercises at home will gradually ramp up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise alone
Description: Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMT and Exercise
Description: Combining IMT training and exercise
Study: NCT01569113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)
Description: UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + ethinylestradiol/levonorgestrel
Description: placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
Study: NCT04220736

Intervention type: DIAGNOSTIC_TEST
Intervention: Computation of quantitative flow ratio
Description: Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computation of quantitative flow ratio
Description: Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
Study: NCT03214523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Education
Description: The subject will undergo a 30-minute session on sleep education from one of the study coordinators.
Study: NCT04391829

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ejaculated semen sample
Description: SARS-CoV-2 positive men will be asked to give an ejaculated semen sample, within the seven days after positive testing. Semen samples will be performed every 7 days, until 2 semen PCR tests are negative and will be retested after 3 months.
Study: NCT03151954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: functional endonasal sinus surgery
Description: collect nasal polyps from patients

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nasal septal construction
Description: collect inferior turbinates from patients as control arm
Study: NCT00844974

Intervention type: OTHER
Group type: OTHER
Intervention: Prevalence
Description: Mood and cognitive assessments
Study: NCT01049282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen (Ag85B-ESAT-6)
Description: Solution for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen (Ag85B-ESAT-6) with adjuvant (IC31)
Description: Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen (Ag85B-ESAT-6) with adjuvant (IC31)
Description: Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen (Ag85B-ESAT-6) with adjuvant (IC31)
Description: Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
Study: NCT03614728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3326595
Description: GSK3326595 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3326595
Description: GSK3326595 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3326595
Description: GSK3326595 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacitidine
Description: 5-Azacitidine will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacitidine
Description: 5-Azacitidine will be administered.
Study: NCT04411251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature-near integrative day care unit programme
Description: Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional integrative day care unit programme
Description: Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
Study: NCT00903292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib (Tarceva)
Description: chemotherapy with erlotinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed (Alimta)
Description: Chemotherapy with pemetrexed
Study: NCT01342991

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Haemorrhoidectomy
Description: The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Haemorrhoidectomy
Description: The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given
Study: NCT03348527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-Hydroxyflutamide Depot
Description: Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-Hydroxyflutamide Depot
Description: Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-Hydroxyflutamide Depot
Description: Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-Hydroxyflutamide Depot
Description: Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide
Study: NCT02305134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tipepidine Hibenzate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04339634

Intervention type: OTHER
Intervention: Simulation of Repurposed Drugs for COVID-19
Description: This study is a simulation of adding repurposed drugs for COVID-19. We are using drug claims, and will not intervene with patient care.